Aminotransferase and gamma-glutamyltranspeptidase levels in obesity are associated with insulin resistance and the metabolic syndrome

Journal of Endocrinological Investigation

Volumn 28, Issue 4, 2005, Pages 333-339

  Marchesini, G ^a,k   Avagnina, S ^b,k   Barantani, E G ^c,k   Ciccarone, A M ^d,k   Corica, F ^e,k   Dall'Aglio, E ^f,k   Dalle Grave, R ^g,k   Morpurgo, P S ^h,k   Tomasi, F ^i,k   Vitacolonna, E ^j,k   Baraldi, L ^k   Forlani, G ^k   Villanova, N ^k   Melchionda, N ^k   Belfiore, F ^k   Capani, F ^k   Taraborrelli, M ^k   Barbieri, S ^k   Scalambra, E ^k   Scutari, C ^k   Corsonello, A ^k   Mirone, S ^k   Beck Peccoz, P ^k   Adami, A ^k   Ferrari, E ^k   Magri, F ^k   Hacker, S ^k   Chatzianagnostou, K ^k   Ferrero, L ^k   more..

^a UNIVERSITY OF BOLOGNA   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

^c San Giuseppe Hospital   (Italy)

^d UNIVERSITY OF PISA   (Italy)

^e UNIVERSITY OF MESSINA   (Italy)

^f UNIVERSITY OF PARMA   (Italy)

^g Villa Garda Hospital   (Italy)

^h UNIVERSITY OF MILAN   (Italy)

ⁱ S ANNA HOSPITAL   (Italy)

^j UNIVERSITY OF CHIETI   (Italy)

^k Bologna ^*

more..

Author keywords

Enzyme levels; Fatty liver; Insulin; Obesity

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; LIVER ENZYME;

ADULT; AGED; ARTICLE; BODY MASS; CLINICAL FEATURE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GROUPS BY AGE; HOSPITAL; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIVER NECROSIS; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; SEX DIFFERENCE; BLOOD; CLINICAL TRIAL; CROSS-SECTIONAL STUDY; DISEASE COURSE; ENZYMOLOGY; FATTY LIVER; LIVER; MIDDLE AGED; MULTICENTER STUDY; NECROSIS; PATHOLOGY; PATHOPHYSIOLOGY; REGRESSION ANALYSIS; RISK FACTOR;

ADULT; AGED; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FATTY LIVER; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; INSULIN RESISTANCE; LIVER; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NECROSIS; OBESITY; REGRESSION ANALYSIS; RISK FACTORS;

EID: 23044476866     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03347199     Document Type: Article

References (40)

1. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors 2001. JAMA 2003, 289: 76-9.
2. WHO Consultation. Definition, diagnosis and classification of diabetes mellitus and its complications. Geneva: World Health Organization; WHO/NCD/NCS/99.2, 1999.
3. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001, 285: 2486-97.
4. Kichian K, McLean R, Gramlich LM, Bailey RJ, Bain VG. Nonalcoholic fatty liver disease in patients investigated for elevated liver enzymes. Can J Gastroenterol 2003, 17: 38-42.
5. Cortez-Pinto H, Camilo ME, Baptista A, De Oliveira AG, De Moura MC. Non-alcoholic fatty liver: another feature of the metabolic syndrome? Clin Nutr 1999, 18: 353-8.
6. Chitturi S, Abeygunasekera S, Farrell G, et al. NASH and insulin resistance: insulin secretion and specific association with the insulin resistance syndrome. Hepatology 2002, 35: 373-9.
7. Pagano G, Pacini G, Musso G, et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 2002, 35: 367-72.
8. Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999, 107: 450-5.
9. Bellentani S, Saccoccio G, Masutti F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000, 132: 112-7.
10. Marceau P, Biron S, Hould FS, et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 1999, 84: 1513-7.
11. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001, 121: 91-100.
12. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003, 98: 960-7.
13. Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2003, 124: 71-9.
14. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003, 37: 917-23.
15. Mofrad P, Contos MJ, Haque M, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003, 37: 1286-92.
16. Vozarova B, Stefan N, Lindsay RS, et al. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 2002, 51: 1889-95.
17. Ohlson LO, Larsson B, Bjorntorp P, et al. Risk factors for type 2 (non-insulin-dependent) diabetes mellitus. Thirteen and one-half years of follow-up of the participants in a study of Swedish men born in 1913. Diabetologia 1988, 31: 798-805.
18. Perry IJ, Wannamethee SG, Shaper AG. Prospective study of serum gamma-glutamyltransferase and risk of NIDDM. Diabetes Care 1998, 21: 732-7.
19. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from plasma fasting glucose and insulin concentrations in man. Diabetologia 1985, 28: 412-9.
20. Melchionda N, Marchesini G, Apolone G, et al. The QUOVADIS study. Features of obese Italian patients seeking treatment at specialist centers. Diabetes Nutr Metab 2003, 16: 115-24.
21. Guidelines Subcommittee. 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999, 17: 151-83.
22. Bellentani S, Tiribelli C, Saccoccio G, et al. Prevalence of chronic liver disease in the general population of northern Italy: the Dionysos Study. Hepatology 1994, 20: 1442-9.
23. Perlemuter G, Sabile A, Letteron P, et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J 2002, 16: 185-94.
24. Sanyal AJ, Contos MJ, Sterling RK, et al. Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndrome. Am J Gastroenterol 2003, 98: 2064-71.
25. Loguercio C, De Simone T, D'Auria MV, et al. Non-alcoholic fatty liver disease: a multicenter clinical study by the Italian Association for the Study of the Liver. Dig Liver Dis 2004, 36: 398-405.
26. Sorbi D, Boynton J, Lindor KD. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol 1999, 94: 1018-22.
27. Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002, 137: 1-10.
28. Stranges S, Dorn JM, Muti P, et al. Body fat distribution, relative weight, and liver enzyme levels: A population-based study. Hepatology 2004, 39: 754-63.
29. Hsiao TJ, Chen JC, Wang JD. Insulin resistance and ferritin as major determinants of nonalcoholic fatty liver disease in apparently healthy obese patients. Int J Obes Relat Metab Disord 2004, 28: 167-72.
30. Schwimmer JB, Deutsch R, Rauch JB, Behling C, Newbury R, Lavine JE. Obesity, insulin resistance, and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease. J Pediatr 2003, 143: 500-5.
31. Katz A, Nambi SS, Mather K, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000, 85: 2402-10.
32. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991, 14: 173-94.
33. Cheal KL, Abbasi F, Lamendola C, McLaughlin T, Reaven GM, Ford ES. Relationship to insulin resistance of the adult treatment panel III diagnostic criteria for identification of the metabolic syndrome. Diabetes 2004, 53: 1195-200.
34. Jeong SK, Nam HS, Rhee JA, Shin JH, Kim JM, Cho KH. Metabolic syndrome and ALT: a community study in adult Koreans. Int J Obes Relat Metab Disord 2004, 28: 1033-8.
35. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001, 50: 1844-50.
36. Lewis GF, Steiner G. Acute effects of insulin in the control of VLDL production in humans. Implications for the insulin-resistant state. Diabetes Care 1996, 19: 390-3.
37. Feldstein AE, Canbay A, Angulo P, et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003, 125: 437-43.
38. Marchesini G, Melchionda N, Apolone G, et al. The metabolic syndrome in treatment-seeking obese persons. Metabolism 2004, 53: 435-40.
39. Ueno T, Sugawara H, Sujaku K, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997, 27: 103-7.
40. Hickman IJ, Jonsson JR, Prins JB, et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 2004, 53: 413-9.